![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Octavius Fenofibrate](https://www.pharmacompass.com/image/flap/octavius-fenofibrate-desktop-headergif-34340.gif)
![Octavius Fenofibrate](https://www.pharmacompass.com/image/flap/octavius-fenofibrate-mobgif-65771.gif)
Active Filter(s):
Details:
Fenofibrate reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolopoprotein B to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia.
Lead Product(s): Fenofibrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Fenofibrate-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
In the researchers' study in the Hebrew University's MicroTissue Lab, Fenofibrate was found to be effective in treating infected human tissue. Its effectiveness will now have to be proven in human clinical trials.
Lead Product(s): Fenofibrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020